Gynaecological oncology research

We are a leader in local, national and international gynaecological cancer research encompassing basic science, histopathology, molecular genetics, surgical innovation, peri-operative care, medical oncology, psycho-oncology and survivorship. 

We aim to attract students and fellows from Australia and overseas who wish to undertake doctoral and post-doctoral research, and encourage collaboration between clinicians and research scientists to deliver new and improved treatments to provide unparalleled care to our patients.
 
Given the large number of patients seeking treatment for gynaecological cancers at St John of God Subiaco Hospital, we are well placed to undertake translational research. 

The Gynaecological Cancer Research Group includes scientists, clinical researchers and clinicians who are members of a multidisciplinary team that delivers state wide comprehensive patient care.

Our research aims to improve the outcomes and quality of life of women with gynaecological cancers.
 
  • The third most commonly diagnosed cancer in women in Australia is gynaecological cancer, including ovarian, endometrial, cervical and vulval cancers.
  • Gynaecological cancers, including ovarian, endometrial, cervical and uterine cancers, are the third most commonly diagnosed cancer in women in Australia.
  • Gynaecological cancer research will help improve outcomes and survival rates as well as improve detection, education and quality of life for gynaecologic cancer survivors.
  • Attracting the best clinicians and research scientists to our group will deliver new and improved treatments to patients.
 

Our research focuses on patient-reported outcomes and the supportive care of women affected by gynaecological malignancies, gynaecological cancer genetics, the management of patients with cervical pre-cancer and cancer, the epidemiology of gynaecological malignancies and biomarkers to predict histological tumour regression in women with high-grade serous ovarian cancer following neoadjuvant chemotherapy.
We have been a recruiting site for a number of landmark clinical trials in gynaecological cancer surgery and lead national multicentre randomised trials.

Director Gynaecological Cancer Research Group
Dr Paul Cohen MD

Gynaecological Oncologists
Dr Stuart Salfinger
Dr Ganendra Raj Kader Ali Mohan

Pathologists
Dr Adeline Tan
Professor Colin Stewart

Medical Oncologists
Dr Andrew Dean
Dr Martin Buck
Dr Tarek Meniawy

Project Manager
Sanela Bilic

Post-doctoral Research Fellow
Dr Aime Powell PhD

Research Officers
Stephanie Jeffares
Maria Beilin
Kellie Cercarelli

Clinical Trials Pharmacist
Naomi Van Hagen
Meagher N.S., Wang, L., Rambau, P.F., Intermaggio, M.P., Huntsman, D.G., Cohen, P.A., Ramus, S.J., Köbel, M. (2019) A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases. Modern Pathology.

Cabasag, C. J., Butler, J., Arnold, M., Rutherford, M., Bardot, A., Ferlay, J., Morgan, E., Møller, B., Gavin, A., Norell, C. H., Harrison, S., Saint-Jacques, N.,  Eden, M., Rous, B., Nordin, A., Hanna, L., Kwon, J., Cohen, P. A., Altman, A. D., Shack, L., … Soerjomataram, I. (2020). Exploring variations in ovarian cancer survival by age and stage (ICBP SurvMark-2): A populationbased study. Gynecologic oncology, 157(1), 234–244. doi.org/10.1016/j.ygyno.2019.12.047

3. Stewart, L. M., Stewart, C., Spilsbury, K., Cohen, P. A., Jordan, S. (2020). Association between pelvic inflammatory disease, infertility, ectopic pregnancy and the development of ovarian serous borderline tumor, mucinous borderline tumor and low-grade serous carcinoma. Gynecologic oncology, 156 (3), 611–615. doi.org/10.1016/j.ygyno.2020.01.027

Heriot, N., Brand, A., Cohen, P., Hegarty, S., Hyde, S., Leung, Y., Zalcberg, J. R., & Rome, R. (2020).
Developing an Australian multi-module clinical quality registry for gynaecological cancers: a
protocol paper. BMJ open, 10(2), e034579. doi. org/10.1136/bmjopen-2019-034579

Butler, J., Finley, C., Norell, C. H., Harrison, S., Bryant, H., Achiam, M. P., Altman, A. D., Baxter, N., Bentley, J., Cohen, P. A. et al (2020). New approaches to cancer care in a COVID-19 world. The Lancet. Oncology, 21 (7), e339–e340. doi.org/10.1016/S1470-2045 (20)30340-5